Moderna and Merck report positive phase 3 results for personalized melanoma vaccine

Pharmaceutical companies Moderna and Merck have announced promising results from a phase 3 clinical trial involving over 1,100 patients with melanoma, the most dangerous form of skin cancer. The study tested an experimental personalized mRNA vaccine known as intismeran autogene, which is designed based on the specific genetic mutations of each patient's tumor and administered in combination with the established immunotherapy drug Keytruda.

The findings reveal that this combined therapeutic approach reduced the relative risk of melanoma recurrence or death by 42%. Furthermore, the risk of developing distant metastases or death was reduced by 38% compared to standard treatments. This marks a significant milestone as the first successful late-stage clinical trial demonstrating that this specific mRNA technology can effectively augment the success of existing immunotherapy protocols.

Detailed results from the study, covering approximately two years of follow-up data, are scheduled to be presented on Saturday, October 24, at the European Society for Medical Oncology (ESMO) congress in Madrid. The scientific community views these results as a major development in the potential for a new generation of cancer treatments tailored to the unique biological profiles of individual patients.